CoChat

Effects of Recombinant Human Growth Hormone in Anorexia Nervosa: A Randomized, Placebo-Controlled Study

Open access
Fazeli, Pouneh K., Lawson, Elizabeth A., Prabhakaran, Rajani, Miller, Karen K., Donoho, Daniel A., Clemmons, David R., Herzog, David B., Misra, Madhusmita, Klibanski, Anne · 2010 · The Journal of Clinical Endocrinology & Metabolism
Cited by 112

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

CONTEXT: Anorexia nervosa (AN), a state of chronic nutritional deprivation, is characterized by GH resistance with elevated GH levels and decreased levels of IGF-I. The effects of supraphysiological recombinant human GH (rhGH) on GH resistance in AN are not currently known. OBJECTIVE: The aim was to investigate whether supraphysiological rhGH increases IGF-I levels in AN. DESIGN AND SETTING: We conducted a randomized, placebo-controlled study in a Clinical Research Center. PATIENTS: We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo. INTERVENTIONS: rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk. MAIN OUTCOME MEASURES: IGF-I, N-terminal propeptide of type 1 procollagen, type I collagen C-telopeptide, glucose, and insulin levels were measured at wk 0, 1, 2, 3, 4, 8, and 12; C-terminal propeptide of type 1 procollagen, leptin, and free fatty acid levels were measured at wk 0 and 12. Body composition, including total fat and lean mass, was measured by dual-energy x-ray absorptiometry at wk 0 and 12. RESULTS: IGF-I levels did not differ between the groups at baseline or after treatment (median after 12 wk-rhGH, 124 ng/ml, interquartile range, 94.5, 170.3; vs. placebo, 85.5 ng/ml, interquartile range, 62, 139; P = 0.3). Similarly, changes in glucose, insulin, free fatty acids, and bone markers did not differ between the groups. Total fat mass and percentage fat mass (rhGH, -2.5 ± 0.6%, vs. placebo, 2.2 ± 1.1%; P = 0.004) decreased significantly in the rhGH group compared to placebo despite comparable weight. CONCLUSIONS: Supraphysiological rhGH administration decreases fat mass in AN without increasing IGF-I levels, supporting the role of GH as a mediator of lipolysis independent of IGF-I.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2010-0493

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 112

Metadata

Authors
Fazeli, P. K., Lawson, E. A., Prabhakaran, R., Miller, K. K., Donoho, D. A., Clemmons, D. R., Herzog, D. B., Misra, M., & Klibanski, A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-11
Volume
95
Issue
11
Pages
4889-4897
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2073627809
Cited by
112
References
2
FWCI
6.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Recombinant Human Growth Hormone in Anorexia Nervosa: A Randomized, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1210/jc.2010-0493
The paper
Fazeli, P. K., Lawson, E. A., Prabhakaran, R., Miller, K. K., Donoho, D. A., Clemmons, D. R., Herzog, D. B., Misra, M., & Klibanski, A. (2010). Effects of Recombinant Human Growth Hormone in Anorexia Nervosa: A Randomized, Placebo-Controlled Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0493

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.